|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
various biotech firms
|
|
gptkbp:awards
|
industry recognition
|
|
gptkbp:clinical_trial
|
infectious diseases
vaccine efficacy
safety assessments
COVID-19 vaccines
|
|
gptkbp:collaboration
|
academic institutions
international health organizations
|
|
gptkbp:community_engagement
|
health initiatives
|
|
gptkbp:community_impact
|
public health
|
|
gptkbp:employees
|
over 10,000
|
|
gptkbp:focus
|
vaccine development
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:funding
|
government grants
private investments
|
|
gptkbp:headquarters
|
gptkb:Beijing,_China
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm Bio
|
|
gptkbp:innovation
|
vaccine technology
|
|
gptkbp:invention
|
biopharmaceutical innovations
|
|
gptkbp:market
|
global
|
|
gptkbp:market_launch
|
COVID-19 vaccines
|
|
gptkbp:market_position
|
gptkb:Africa
gptkb:Middle_East
gptkb:Asia
gptkb:Latin_America
|
|
gptkbp:notable_products
|
BBIBP-Cor V
WIBP-Cor V
|
|
gptkbp:parent_company
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:partnership
|
gptkb:World_Health_Organization
local governments
|
|
gptkbp:product_type
|
vaccines
|
|
gptkbp:regulatory_compliance
|
multiple countries
|
|
gptkbp:research_and_development
|
biologics
|
|
gptkbp:revenue
|
billions of USD
|
|
gptkbp:strategic_goals
|
gptkb:collaboration
gptkb:expansion
innovation
sustainability
community health
|
|
gptkbp:subsidiary
|
Sinopharm Vaccine Technology Co.
|
|
gptkbp:supply_chain
|
global distribution
|
|
gptkbp:sustainability
|
environmental practices
|
|
gptkbp:bfsParent
|
gptkb:China_National_Pharmaceutical_Group_Corporation
|
|
gptkbp:bfsLayer
|
5
|